PMS-OLMESARTAN-HCTZ TABLET

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

Disponible desde:

PHARMASCIENCE INC

Código ATC:

C09DA08

Designación común internacional (DCI):

OLMESARTAN MEDOXOMIL AND DIURETICS

Dosis:

25MG; 40MG

formulario farmacéutico:

TABLET

Composición:

HYDROCHLOROTHIAZIDE 25MG; OLMESARTAN MEDOXOMIL 40MG

Vía de administración:

ORAL

Unidades en paquete:

30/100/1000

tipo de receta:

Prescription

Área terapéutica:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Resumen del producto:

Active ingredient group (AIG) number: 0252502003; AHFS:

Estado de Autorización:

CANCELLED PRE MARKET

Fecha de autorización:

2019-02-07

Ficha técnica

PRODUCT MONOGRAPH
Pr
PMS-OLMESARTAN-HCTZ
Olmesartan Medoxomil and Hydrochlorothiazide Tablets
20 mg/12.5 mg, 40 mg/12.5 mg, and 40 mg/25 mg
Angiotensin II AT
1
Receptor Blocker - Diuretic
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Quebec
H4P 2T4
www.pharmascience.com
DATE OF REVISION:
June 28, 2017
Submission Control No.: 205707, 200930
_ _
_pms-OLMESARTAN-HCTZ Product Monograph _
_Page 2 of 35_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................16
OVERDOSAGE
................................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND STABILITY
..........................................................................................22
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................22
PART II: SCIENTIFIC INFORMATION
...............................................................................23
PHARMACEUTICAL INFORMATION
..........................................................................23
CLINICAL TRIALS
.....................................................................